Quality Compounder

542 tickers in this investment thesis
Ranks this page's recent reports by score.
CorVel Corporation
CRVL·Financials
A ★★★★Buy
Current$85.91
Target$91.20
Return+6.2%
Nov 6, 2026

CorVel combines durable claims management relationships, exceptional capital efficiency, and automation-driven earnings growth, although its premium valuation requires sustained execution and leaves limited room for disappointment.

Score
76
Zebra Technologies Corporation
ZBRA·Technology
A ★★★★Buy
Current$321.64
Target$414.00
Return+28.7%
Nov 6, 2026

Zebra Technologies combines entrenched enterprise identification systems, growing automation demand, and strong free cash flow with an attractive valuation, although memory-cost inflation and cyclical hardware spending threaten margin recovery.

Score
84
DuPont de Nemours, Inc.
DD·Materials
B ★★★Hold
Current$145.03
Target$160.80
Return+10.9%
Nov 6, 2026

DuPont's focused specialty-materials portfolio and improving margins support sustainable earnings growth, but modest capital efficiency, legacy liabilities and an already reasonable valuation limit near-term upside.

Score
73
Waters Corporation
WAT·Healthcare
B ★★★Hold
Current$453.08
Target$472.50
Return+4.3%
Nov 6, 2026

Waters combines durable laboratory instrumentation, recurring consumables, and expanding diagnostics exposure with meaningful synergy opportunities, but elevated leverage and demanding cash-flow expectations limit its near-term investment appeal.

Score
68
Coca-Cola Europacific Partners PLC
CCEP·Consumer Staples
B ★★★Hold
Current$117.29
Target$113.00
Return-3.7%
Nov 6, 2026

Coca-Cola Europacific Partners combines a durable beverage distribution moat, resilient cash flow and disciplined shareholder returns, but elevated valuation and substantial leverage limit near-term upside.

Score
69
AMETEK, Inc.
AME·Industrials
A ★★★★Buy
Current$222.99
Target$249.60
Return+11.9%
Nov 6, 2026

AMETEK combines high-margin precision instrumentation, durable customer switching costs, and acquisition-driven compounding, while elevated debt and Indicor integration requirements create meaningful execution risks.

Score
79
Apollo Global Management, Inc.
APO·Financials
B ★★★Hold
Current$117.27
Target$138.84
Return+18.4%
Nov 6, 2026

Apollo's integrated private-credit and retirement platform offers durable recurring earnings growth, but insurance valuation volatility and credit-cycle sensitivity constrain near-term conviction.

Score
73
Itaú Unibanco Holding S.A.
ITUB·Financials
A ★★★★Buy
Current$7.29
Target$8.60
Return+18.0%
Nov 6, 2026

Itaú Unibanco combines a durable Brazilian banking franchise, strong recurring ROE, and attractive earnings multiples, although political uncertainty, currency depreciation, and credit-cycle deterioration could constrain shareholder returns.

Score
78
Amgen Inc.
AMGN·Healthcare
B ★★★Hold
Current$460.28
Target$442.62
Return-3.8%
Nov 6, 2026

Amgen combines a durable biotechnology franchise, strong cash generation, and growing specialty medicines, but elevated valuation, biosimilar erosion, and acquisition-related leverage constrain prospective returns.

Score
67
Assurant, Inc.
AIZ·Financials
A ★★★★Buy
Current$306.87
Target$336.00
Return+9.5%
Nov 6, 2026

Assurant combines recurring specialty insurance and protection-service earnings with strong cash generation and disciplined buybacks, although catastrophe exposure, partner concentration, and a higher share price constrain its margin of safety.

Score
81
Ball Corporation
BALL·Consumer Discretionary
B ★★★Hold
Current$66.91
Target$71.84
Return+7.4%
Nov 6, 2026

Ball's global aluminum packaging franchise, improving comparable EPS, and disciplined buybacks support long-term value creation, but weak cash conversion, leverage, and a premium to packaging peers limit near-term upside.

Score
68